Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Lutetium-177 Vipivotide Tetraxetan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Pluvicto

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Pluvicto

    Lutetium Lu 177 Vipivotide Tetraxetan

    arrow
    Bioprocess International Europe
    Not Confirmed

    Brand Name : Pluvicto

    Switzerland
    arrow
    Bioprocess International Europe
    Not Confirmed

    Novartis

    Lutetium Lu 177 Vipivotide Tetraxetan

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 271

    2021 Revenue in Millions : 0

    Growth (%) : 100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Pluvicto

    Lutetium Lu 177 Vipivotide Tetraxetan

    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed

    Brand Name : Pluvicto

    Switzerland
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed

    Novartis

    Lutetium Lu 177 Vipivotide Tetraxetan

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 980

    2022 Revenue in Millions : 271

    Growth (%) : 262

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Pluvicto

    Lutetium Lu 177 Vipivotide Tetraxetan

    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed

    Brand Name : Pluvicto

    Switzerland
    arrow
    Stanford Drug Discovery Symposium
    Not Confirmed

    Novartis

    Lutetium Lu 177 Vipivotide Tetraxetan

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 1,392

    2023 Revenue in Millions : 980

    Growth (%) : 42

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.